Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending October 17, 2006. The report details a specific corporate action regarding the repurchase of the company's own ordinary shares.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to the share repurchase transaction:
- Shares Purchased: 205,000 ordinary shares of 25 pence each.
- Purchase Price: 1,466.97 pence per share.
- Treasury Shares Held: 200,546,678 shares following the transaction.
- Shares in Issue: 5,786,156,304 shares (excluding Treasury shares).
Material Changes
The material change reported is the reduction of outstanding shares through a buyback executed on October 17, 2006. This action was taken under authority granted by shareholders at the Annual General Meeting on May 17, 2006. The filing does not provide comparative data against prior periods for operational metrics.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies beyond the specific share repurchase announcement. The document explicitly states it does not constitute an offer or solicitation to purchase securities.
Investor Verification Points
- Verify the total cost of the repurchase (205,000 shares at 1,466.97 pence) against the company's cash position in the most recent full financial report.
- Confirm the updated total share count and Treasury holdings in subsequent filings.
- Review the May 17, 2006 Annual General Meeting minutes to understand the full scope of the share buyback authorization.